The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The comparative efficacy of atezolizumab and bevacizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).
 
David Trueman
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BD Medical (Inst); Biomarin (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Janssen-Cilag (Inst); Lifescan Pharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sarepta Therapeutics (Inst); Takeda (Inst)
 
Yifeng Liu
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Becton Dickinson (Inst); Biomarin (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Janssen-Cilag (Inst); Lifescan Pharma (Inst); Novartis (Inst); Pfizer (Inst); ResApp Health (Inst); Roche (Inst); Sanofi (Inst); Sarepta Therapeutics (Inst); Takeda (Inst)
 
Melanie Lucero
Employment - Eisai
Stock and Other Ownership Interests - Medtronic
 
Genevieve Meier
Employment - Eisai